Host-based prophylaxis successfully targets liver stage malaria parasites

Molecular Therapy

Volumn 23, Issue 5, 2015, Pages 857-865

  Douglass, Alyse N ^a   Kain, Heather S ^a   Abdullahi, Marian ^a   Arang, Nadia ^a   Austin, Laura S ^a,b   Mikolajczak, Sebastian A ^a   Billman, Zachary P ^b   Hume, Jen C C ^a   Murphy, Sean C ^b   Kappe, Stefan H I ^a,b   Kaushansky, Alexis ^a  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; NUTLIN 3; OBATOCLAX; PROTEIN BCL 2; PROTEIN P53; SERDEMETAN; ANTIMALARIAL AGENT; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; GROWTH INHIBITION; HEPATITIS; HOST PARASITE INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LIVER CELL; MALARIA; MALE; MOUSE; NONHUMAN; PARASITE IDENTIFICATION; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DISEASE MODEL; DRUG EFFECTS; FEMALE; LIFE CYCLE STAGE; LIVER; MALARIA, FALCIPARUM; METABOLISM; PARASITE LOAD; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM; POST EXPOSURE PROPHYLAXIS; TRANSGENIC MOUSE;

MUS; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIMALARIALS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; IMIDAZOLES; LIFE CYCLE STAGES; LIVER; MALARIA; MALARIA, FALCIPARUM; MICE; MICE, TRANSGENIC; PARASITE LOAD; PIPERAZINES; PLASMODIUM; PLASMODIUM FALCIPARUM; POST-EXPOSURE PROPHYLAXIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929046469     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.18     Document Type: Article

References (44)

1. Kappe SH, Vaughan AM, Boddey JA and Cowman AF. (2010). That was then but this is now: malaria research in the time of an eradication agenda. Science 328: 862-866
2. Muregi FW. (2010). Antimalarial drugs and their useful therapeutic lives: rational drug design lessons from pleiotropic action of quinolines and artemisinins. Curr Drug Discov Technol 7: 280-316
3. Arrow KJ, Panosian C and Gelband H. (2004). Antimalarial drugs and drug resistance. In: Arrow KJ, Panosian C and Gelband H (eds). Saving Lives Buying Time: Economics of Malaria Drugs in an Age of Resistance. Washington DC: National Academies Press
4. Sibley CH and Price RN. (2012). Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. Int J Parasitol Drugs Drug Resist 2: 126-133
5. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. (2014). A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505: 50-55
6. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al.; Tracking Resistance to Artemisinin Collaboration (TRAC). (2014). Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371: 411-423
7. Polo-Hernández E, Tello V, Arroyo AA, Domínguez-Prieto M, De Castro F, Tabernero A, et al. (2014). Oleic acid synthesized by stearoyl-CoA desaturase (SCD-1) in the lateral periventricular zone of the developing rat brain mediates neuronal growth migration and the arrangement of prospective synapses. Brain Res 1570: 13-25
8. White NJ. (2011). Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10: 297
9. Kaiser K, Camargo N and Kappe SH. (2003). Transformation of sporozoites into early exoerythrocytic malaria parasites does not require host cells. J Exp Med 197: 1045-1050
10. Kaushansky A, Ye, AS, Austin LS, Mikolajczak SA, Vaughan AM, Camargo N, et al. (2013). Suppression of host p53 is critical for Plasmodium liver-stage infection. Cell Rep 3: 630-637
11. Albuquerque SS, Carret C, Grosso AR, Tarun AS, Peng X, Kappe SH, et al. (2009). Host cell transcriptional profiling during malaria liver stage infection reveals a coordinated and sequential set of biological events. BMC Genomics 10: 270
12. Li, T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. (2012). Tumor suppression in the absence of p53-mediated cell-cycle arrest apoptosis and senescence. Cell 149: 1269-1283
13. Kaushansky A, Metzger PG, Douglass AN, Mikolajczak SA, Lakshmanan V, Kain HS, et al. (2013). Malaria parasite liver stages render host hepatocytes susceptible to mitochondria-initiated apoptosis. Cell Death Dis 4: e762
14. Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP. (2009). Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873
15. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, et al. (2008). A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14: 8295-8301
16. Hartman ML and Czyz M. (2012). Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy. Anticancer Agents Med Chem 12: 966-981
17. Selleck Chem Website. (2014). http://www.selleckchem.com
18. Billard C. (2013). BH3 mimetics: status of the field and new developments. Mol Cancer Ther 12: 1691-1700
19. Wongsrichanalai C, Pickard AL, Wernsdorfer WH and Meshnick SR. (2002). Epidemiology of drug-resistant malaria. Lancet Infect Dis 2: 209-218
20. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681
21. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517
22. Yuan Y, Liao YM, Hsueh CT and Mirshahidi HR. (2011). Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 4: 16
23. Kaushansky A and Kappe SH. (2011). The crucial role of hepatocyte growth factor receptor during liver-stage infection is not conserved among Plasmodium species. Nat Med 17: 1180-1181; author reply 1181
24. Silvie O, Rubinstein E, Franetich JF, Prenant M, Belnoue E, Rénia L, et al. (2003). Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat Med 9: 93-96
25. Vaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, et al. (2012). Complete Plasmodium falciparum liver-stage development in liverchimeric mice. J Clin Invest 122: 3618-3628
26. Mackinnon MJ and Marsh K. (2010). The selection landscape of malaria parasites. Science 328: 866-871
27. Crompton PD, Moebius J, Portugal S, Waisberg M, Hart G, Garver LS, et al. (2014). Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Annu Rev Immunol 32: 157-187
28. Del Gaizo Moore V and Letai A. (2013). BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332: 202-205
29. Takehara T, Tatsumi T, Suzuki T, Rucker EB 3rd, Hennighausen L, Jinushi M, et al. (2004). Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127: 1189-1197
30. Johnson RF and Perkins ND. (2012). Nuclear factor-βB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci 37: 317-324
31. Berkers CR, Maddocks OD, Cheung EC, Mor I and Vousden KH. (2013). Metabolic regulation by p53 family members. Cell Metab 18: 617-633
32. Rufini A, Tucci P, Celardo I and Melino G. (2013). Senescence and aging: the critical roles of p53. Oncogene 32: 5129-5143
33. Shay JW, Pereira-Smith OM and Wright WE. (1991). A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 196: 33-39
34. Sibley CH. (2014). Understanding drug resistance in malaria parasites: basic science for public health. Mol Biochem Parasitol 195: 107-114
35. Tabernero P, Fernández FM, Green M, Guerin PJ and Newton PN. (2014). Mind the gaps-the epidemiology of poor-quality anti-malarials in the malarious world-analysis of the WorldWide Antimalarial Resistance Network database. Malar J 13: 139
36. Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, et al. (2011). A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res 17: 6313-6321
37. Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, et al. (2012). A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer 106: 839-845
38. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, et al. (2012). Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119: 2171-2172
39. Fauci AS and Challberg MD. (2005). Host-based antipoxvirus therapeutic strategies: turning the tables. J Clin Invest 115: 231-233
40. Hawn TR, Matheson AI, Maley SN and Vandal O. (2013). Host-directed therapeutics for tuberculosis: can we harness the host?. Microbiol Mol Biol Rev 77: 608-627
41. Law GL, Korth MJ, Benecke AG and Katze MG. (2013). Systems virology: hostdirected approaches to viral pathogenesis and drug targeting. Nat Rev Microbiol 11: 455-466
42. Lee SM and Yen HL. (2012). Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res 96: 391-404
43. Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK, et al. (2005). Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 115: 379-387
44. Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, et al. (2012). Obatoclax saliphenylhalamide and gemcitabine inhibit influenza a virus infection. J Biol Chem 287: 35324-35332